Skip to main content
SpringerLink
Log in
Book cover

Principles of Cancer Biotherapy pp 463–492Cite as

Cancer Biotherapy: 1998 Disease-Related Activity

  • Chapter

  • 104 Accesses

Abstract

The 1990s will witness a burgeoning number of biologicals under clinical investigation, either singly or in combination with other biologicals or chemotherapeutic agents. Already, biotherapies have demonstrated efficacy against certain malignancies. It is expected that their assimilation into our standard anticancer armamentarium will continue to broaden in the 1990s, leading to the dominance of biotherapy in cancer treatment soon after the year 2000. This chapter will summarize disease-related activity for selected biotherapies as we complete the final decade of this millennium.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrams DI, Volberding PA. Alpha interferon therapy of AIDS-associated Kaposi’s sarcoma. Semin Oncol 1986; 13(32): 43–47.

    PubMed  CAS  Google Scholar 

  2. Adler A, Gillon G, Lurie H, et al. Active specific immunotherapy of renal cell carcinoma patients: A prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Response Mod 1987; 6: 610–624.

    PubMed  CAS  Google Scholar 

  3. Ajani JA, Rios AA, Ende K, et al. Phase I and II studies of the combination of recombinant human interferongamma and 5-fluorouracil in patients with advanced colorectal carcinoma. J Biol Response Modif 1989; 8: 140–146.

    CAS  Google Scholar 

  4. Al-Kativ A, Wang CY, Koziner V Gamma interferon (IFN-gamma)-induced phenotypic changes of chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) cells. Proc AACR 1984; 25: 235.

    Google Scholar 

  5. Alimena G, Morra E, Lazzarino M, et al. Interferon-a2b as therapy for Ph1-positive chronic myelogenous leukemia: A study of 82 patients treated with intermittent or daily administration. Blood 1988; 72: 642–647.

    PubMed  CAS  Google Scholar 

  6. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624–2633.

    PubMed  CAS  Google Scholar 

  7. Atkins MB, O’Boyle KR, Sosman JA. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1994; 12: 1553–1560.

    PubMed  CAS  Google Scholar 

  8. Aulitzky W, Gastl G, Aulitzky WE, et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 1989; 7: 1875–1884.

    PubMed  CAS  Google Scholar 

  9. Austin FC, Boone CW, Levin DL, et al. Breast cancer skin test antigens of increased sensitivity prepared from vesicular stomatitis virus infected tumor cells. Cancer 1982; 49: 2034–2042.

    Article  PubMed  CAS  Google Scholar 

  10. Avner BP, Liao SK, Avner B, et al. Therapeutic murine monoclonal antibodies developed for individual cancer patients. J Biol Response Modif 1989; 8(1) 25–36.

    CAS  Google Scholar 

  11. Babaian RJ, Murray JL, Lamkie LM, et al. Radioimmunological imaging of metastatic prostatic cancer with 111 indium-labeled monoclonal antibody PAY 276. J Urol 1987; 137(3) 439–43.

    PubMed  CAS  Google Scholar 

  12. Badger. Proc AACR 1987; 28: 338.

    Google Scholar 

  13. Bajetta E, Negretti E, Giannotti B. Phase II study of interferon alpha 2a and dacarbazine in advanced melanoma. Am J Clin Oncol 1990; 13:405–409.

    Article  PubMed  CAS  Google Scholar 

  14. Bajorin D, Chapman P, Kunicka J, et al. Phase I trial of a combination of R24 mouse monoclonal antibody and recombinant interleukin-2 in patients with melanoma. Proc ASCO 1987; 6: 210.

    Google Scholar 

  15. Bajorin DF, Chapman PB, Dimaggio J, et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990; 50: 7490–7495.

    PubMed  CAS  Google Scholar 

  16. Bakke A, Gothlin JH, Haukaas SA, Kalland T. Augmentation of natural killer cell activity after arterial embolization of renal carcinomas. Cancer Res 1982; 42: 3880–3883.

    PubMed  CAS  Google Scholar 

  17. Bakker W, Nijhuis-Heddes JMA, van der Velde EA. Postoperative intrapleural BCG in lung cancer: a 5-year follow- up report. Cancer Immunol Immunother 1986; 22: 155–159.

    Article  PubMed  CAS  Google Scholar 

  18. Ball ED, Bernier GM, Cornwell GG. Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia. Blood 1983; 62:1203–1210.

    PubMed  CAS  Google Scholar 

  19. Berek JS, Hacker NF, Lichtenstein A. Intraperitoneal recombinant alpha-interferon for ‘salvage’ immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Semin Oncol 1986; XIII (3 suppl 2): 61–71.

    Google Scholar 

  20. Berek JS, Knapp R, Hacker N. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Proc ASCO 1984; 3: 173.

    Google Scholar 

  21. Blair S, Flaherty L. Valdivieso M. Comparison of high dose interleukin 2 with combined chemotherapy and low dose IL2 in metastatic malignant melanoma. Proc Am Soc Clin Oncol 1991; 10: 294 (abstract).

    Google Scholar 

  22. Yuan D, Handler FJ, Vitetta ES. Characterization of a monoclonal antibody reactive with a subset of human breast tumors. J Natl Cancer Inst 1982; 68: 719–728.

    PubMed  CAS  Google Scholar 

  23. Bonnem EM, Spiegel RJ. Interferon-alpha: current status and future promise. J Biol Response Modif 1984; 3(6) 580–598.

    CAS  Google Scholar 

  24. Bonnem E, Oldham RK. Gamma interferon physiology and potential role in cancer therapy. J Biol Response Modif 1987 6: 275–301.

    CAS  Google Scholar 

  25. Borden EC, Holland JF, Dao TL, et al. Leukocyte derived interferon (alpha) in human breast carcinoma. Ann Intern Med 1982; 97: 1–6.

    PubMed  CAS  Google Scholar 

  26. Borgstrom S, vonEyben FE, Flodgren P, et al. Human leukocyte interferon and cimetidine for metastatic melanoma. N Engl J Med 1982; 307: 1080–1081.

    PubMed  CAS  Google Scholar 

  27. Bouroncle BA, Wiseman BK, Doak CA. Leukemic reticuloendotheliosis. Blood 1958; 13: 609–629.

    PubMed  CAS  Google Scholar 

  28. Brady LW, Woo DV, Karlsson U, et al. Radioimmunotherapy of human gliomas using 1-125 labeled monoclonal antibody to epidermal growth factor receptor. Proc ASCO 1988; 7: 83.

    Google Scholar 

  29. Brichard V, VanPel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178:489–495.

    Article  PubMed  CAS  Google Scholar 

  30. Brown SL, Miller RA, Horning SJ. Treatment of B cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73(3) 651–661.

    PubMed  CAS  Google Scholar 

  31. Brown TD, Koeller J, Beougher K, et al. A phase I clinical trial of recombinant DNA gamma interferon. J Clin Oncol 1987;5:790–798.

    PubMed  CAS  Google Scholar 

  32. Budd GT, Osgood B, Barna B, et al. Phase I clinical trial of interleukin-2 and alpha-interferon: toxicity and immunologic effects. Cancer Res 1989; 49: 6432–6436.

    PubMed  CAS  Google Scholar 

  33. Bunn PA, Ihde DC, Foon KA. The role of recombinant interferon alpha-2A in the therapy of cutaneous T cell lymphomas. Cancer 1986; 57: 1689–1695.

    Article  PubMed  Google Scholar 

  34. Buzaid AC, Todd MB. Therapeutic options in renal cell carcinoma. Semin Oncol 1989; 16(1 suppl 1): 12–19.

    PubMed  CAS  Google Scholar 

  35. Buzdar AU, Blumenschein GR, Hortovagyi GN, et al. Adjuvant chemotherapy with 4-fluorouracil, doxorubicin (Adriamycin) and cyclophosphamide, with or without BCG immunotherapy in state II or stage III breast cancer. In: Terry WD, Rosenberg SA,eds. Immunotherapy of human cancer. New York: Elsevier North Holland, 1982: 175–181.

    Google Scholar 

  36. Bystryn J-C, Jacobsen S, Harris MN, et al. Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Resp Modif 1986; 5:221–224.

    Google Scholar 

  37. Bystryn J-C, Miller K, Cui J, Oratz R. Identification of candidate antigens for construction of melanoma vaccines. Clin Res 1993; 41(2) 489A.

    Google Scholar 

  38. Bystryn J-C, Oratz R, Roses DF, et al. Improved survival of melanoma patients with delayed type hypersensitivity response to melanoma vaccine immunization. Clin Res 1991; 39: 503A.

    Google Scholar 

  39. Cannon GB, McCoy JL, Connor RJ, et al. Use of the leukocyte migration inhibition assay to evaluate antigenic differences in human breast cancers in melanoma. J Natl Cancer Inst 1978; 60: 969–978.

    PubMed  CAS  Google Scholar 

  40. Carrasquillo JA, Bunn PA Jr, Kennan AM, et al. Radioimmunodetection of cutaneous T-cell lymphoma with mIn-T101 monoclonal antibody. N Engl J Med 1986; 315:673–680.

    Article  PubMed  CAS  Google Scholar 

  41. Carrasquillo JA, Abrams PG, Schroff R, et al. Effect of antibody dose on the imaging and biodistribution of indium-111 0.2.27 anti-melanoma monoclonal antibody. J Nucl Med 1988; 29(1): 39–47.

    Google Scholar 

  42. Case DC Jr, Sonneborn HL, Paul SD. Phase II study of rDNA alpha II interferon (Intron-A) in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep 1986; 70(11) 1251–1254.

    PubMed  Google Scholar 

  43. Ceriani RL, Thompson K, Pesterson JA, Abraham S. Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci USA 1977; 74: 582–586.

    Article  PubMed  CAS  Google Scholar 

  44. Ceriani RL, Saki M, Sussman H, et al. Circulating human mammary epithelial antigens in breast cancer. Proc Natl Acad Sci USA 1982; 79: 5420–5424.

    Article  PubMed  CAS  Google Scholar 

  45. Chapman PV, Hakes T, Gabrilove JL. A phase I pilot study of intraperitoneal (I.P.) rIL-2 in ovarian cancer. Proc ASCO 1986; 5:231.

    Google Scholar 

  46. Cheung N-KV, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5: 1430–1440.

    PubMed  CAS  Google Scholar 

  47. Clark RH, Dimitrov NV, Axelson JA, Charmella LJ. Leukocyte interferon as a biological response modifier in lymphoproliferative diseases resistant to standard therapy. Am Soc Hematol 1983; 62: 188a.

    Google Scholar 

  48. Clarkson VD, Dowling MD, Gee TS, et al. Treatment of acute leukemia. Cancer 1975; 36: 775.

    Article  PubMed  CAS  Google Scholar 

  49. Coates A, Railings M, Hersey P, et al. Phase II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res 1986; 6: 1–4.

    Article  PubMed  CAS  Google Scholar 

  50. Cohen MH, Chreten PB, Ihde DC, et al. Thymosin fraction V prolongs the survival of lung cancer patients treated with intensive combination chemotherapy. J Am Med Assoc 1979; 245: 1813–1815.

    Article  Google Scholar 

  51. Coit D, Houghton A, Corden-Cardo C, et al. Isolation limb perfusion with monoclonal antibody R24 in patients with malignant lymphoma. Proc ASCO 1988; 7: 248.

    Google Scholar 

  52. Colcher D, Esteban J, Carrasquillo JA. Complementation of intracavity and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 1987; 47:4218–4224.

    PubMed  CAS  Google Scholar 

  53. Colcher D, Horan-Hand P, Nuti M, Scholm J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981; 78: 3199–3203.

    Article  PubMed  CAS  Google Scholar 

  54. Colcher D, Zalutsky M, Kaplan W, et al. Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res 1983; 43: 736–742.

    PubMed  CAS  Google Scholar 

  55. Cooper MR. Interferons in the treatment of multiple myeloma. Semin Oncol 1986; 13()2): 13–20.

    Google Scholar 

  56. Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (rIFN-aA) in disseminated malignant melanoma. Cancer 1984; 54(12) 2844–2849.

    Article  PubMed  CAS  Google Scholar 

  57. Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (rIFN-aA) in disseminated malignant melanoma. Cancer 1984; 54(12) 2844–2849.

    Article  PubMed  CAS  Google Scholar 

  58. Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 1984; 2: 1002–1005.

    PubMed  CAS  Google Scholar 

  59. Creekmore S, Urba W, Koop W, et al. Phase IB/II trial of R24 antibody and interleukin-2 (IL2) in melanoma. Proc Am Soc Clin Oncol 1992; 1886: 345 (abstract).

    Google Scholar 

  60. Culver KW, Blaese RM. Gene therapy for cancer, [review]. Trends Genet 1994; 10: 174–178.

    Article  PubMed  CAS  Google Scholar 

  61. Cuttitta F, Carney DN, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 1985; 316: 823–826.

    Article  PubMed  CAS  Google Scholar 

  62. Day CL, Lew RA, Mihm MC, Sober AJ. A multivariate analysis of prognostic factors for melanoma patients with lesions >3.65 mm in thickness. The importance of revealing alternative cox models. Ann Surg 1982; 195:44–49.

    Article  PubMed  Google Scholar 

  63. Demchak PA, Mier JW, Robert NJ. Interleukin-2 and high dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 1991; 9: 1821–1830.

    PubMed  CAS  Google Scholar 

  64. Diaz RE, Jimeno J, Camps C, et al. Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. Cancer Invest 1992; 10:259–264.

    Article  Google Scholar 

  65. DeVita VT Jr, Hellman S, Rosenberg SA. Cell transfer therapy: Clinical applications. In: Biologic Therapy of Cancer, 2nd Edition. DeVita VT Jr, Hellman S, Rosenberg SA eds. J.B. Lippincott Company, Philadelphia, 1995:489.

    Google Scholar 

  66. DeVita VT Jr, Hellman S, Rosenberg SA. Cell transfer therapy: Clinical applications. In: Biologic Therapy of Cancer, 2nd Edition. DeVita VT Jr, Hellman S, Rosenberg SA eds. J.B. Lippincott Company, Philadelphia, 1995:501.

    Google Scholar 

  67. Dimitrov NV, Myer C, Einhorn S, et al. Interferon as modifiers of estrogen receptors in cancer tissues. Proc ASCO 1982; 23: 240.

    Google Scholar 

  68. Dillman RO, Beauregard JC, Shawler DL, et al. In: Peters H, ed. Protides of the biological fluids. New York: Pergamon Press, 1983: 353–358.

    Google Scholar 

  69. Dillman RO, Shawler DL, Sobol RE, et al. Murine monoclonal antibody therapy in 2 patients with lymphocytic leukemia. Blood 1982; 59: 1036–1045.

    PubMed  CAS  Google Scholar 

  70. Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and lymphokine activated killer cells alternated with DTIC as treatment of advanced melanoma. J Natl Cancer Inst 1990.

    Google Scholar 

  71. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med 1989; 111: 592–603.

    PubMed  CAS  Google Scholar 

  72. Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and tumor derived activated cells as treatment of advanced melanoma. J Clin Oncol 1990.

    Google Scholar 

  73. Dillman RO, Oldham RK, Barth NM. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a national biotherapy study group trial. J Natl Cancer Inst 1990; 82: 1345–1349.

    Article  PubMed  CAS  Google Scholar 

  74. Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and tumor infiltrating lymphocytes as treatment of advanced melanoma. Cancer 1991; 68(1) 1– 8.

    Google Scholar 

  75. Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine activated killer cells for advanced cancer: an NBSG trial. J Clin Oncol 1991; 9: 1233–1240.

    PubMed  CAS  Google Scholar 

  76. Dillman RO, Church C, Oldham RK, et al. Inpatient continuous infusion interleukin-2 in 788 cancer patients: the NBSG experience. Cancer 1993; 71: 2358–2370.

    Article  PubMed  CAS  Google Scholar 

  77. Dorval T, Palangie T, Jouve M, et al. Clinical phase II trial of recombinant DNA interferon (interferon alfa 2b) in patients with metastatic malignant melanoma. Cancer 1986;58:215–218.

    PubMed  CAS  Google Scholar 

  78. Doyle A, Martin J, Funa K, et al. Markedly decreased expression of class I histocompatibility antigens, protein and mRNA in human small cell lung cancer. J Exp Med 1985;161:1135–1151.

    Article  PubMed  CAS  Google Scholar 

  79. Dutcher JP, Creekmore S, Weiss GR. Phase II study of high-dose interleukin-2 and lymphokine-activated killer cells. J Clin Oncol 1989; 7:477–485.

    PubMed  CAS  Google Scholar 

  80. Dutcher JP, Gaynor ER, Boldt DH, et al. A phase II study of high dose continuous infusion interleukin-2 with lymphokine activated killer cells: Not the optimal schedule for metastatic melanoma. J Clin Oncol 1991; 9: 641–648.

    PubMed  CAS  Google Scholar 

  81. Ellerhorst J, Jones E, Kilbourn R, et al. Fixed low dose gamma interferon is active against metastatic renal cell carcinoma (abstract). Proc Am Soc Clin Oncol 1992; 11: 220.

    Google Scholar 

  82. Elsasser-Beile U, Drews H. Interferon in the treatment of malignant melanoma. Results of clinical studies. Fortschr Med 1987; 105:401.

    PubMed  CAS  Google Scholar 

  83. Epenetos AA, Munro AJ, Stewart S, et al. Antibodyguided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987; 5: 1890–1899.

    PubMed  CAS  Google Scholar 

  84. Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469–475.

    PubMed  CAS  Google Scholar 

  85. Esteban JM, Colcher D, Sugerbaker P, et al. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 1987; 39: 50–59.

    CAS  Google Scholar 

  86. Ettinger DS, Order SE, Wharam MD, et al. Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer. Cancer Treat Rep 1982; 66:289–297.

    PubMed  CAS  Google Scholar 

  87. Fairlaub DJ. Spontaneous regression of metastasis of renal cancer. Cancer 1981; 47:2102–2106.

    Article  Google Scholar 

  88. . Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alpha 2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.J Clin Oncol 1991; 9:1403–1408.

    PubMed  CAS  Google Scholar 

  89. Fer MF, Oldham RK. Protein A immunoadsorption/immunoactivation: a critical review. In: Salinas FA, Hanna MG, eds. Immune complexes and human cancer. Contemporary topics in immunobiology, vol. 15. New York: Plenum Publishing, 1985:257–276.

    Google Scholar 

  90. Fer MF, Beman J, Stevenson HC. A trial of autologous plasma perfusion over protein A in patients with breast cancer. J Biol Response Modif 1984; 3: 352–358.

    CAS  Google Scholar 

  91. Ferradini L, Mackenson A, Genevee C, et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. J Clin Invest 1993; 91: 1183–1190.

    Article  PubMed  CAS  Google Scholar 

  92. Ferraresi R, Rudnick SA, Bonnem EM, et al. Enhanced response to chemotherapy after treatment with DNA alpha-2 interferon. Am Soc Hematol 1983; 62: 212a.

    Google Scholar 

  93. Fiedler W, Jasmin C, DeMulder PHM. A phase II study of sequential recombinant interleukin-2 followed by dacarbazine in metastatic melanoma. Eur J Cancer 1992; 28:443–446.

    Article  PubMed  CAS  Google Scholar 

  94. Figlin RA, Sarna GP. Human leukocyte interferon (alpha IFN): phase II trial in non-small cell lung cancer and adenocarcinoma of the lung. Proc ASCO 1983; 2: 45.

    Google Scholar 

  95. Figlin RA, Belldegrun A, Moldaver N, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992; 10:414–421.

    PubMed  CAS  Google Scholar 

  96. Flaherty LE, Redman BG, Chabot GG. A Phase I-II study of dacarbazine in combination with outpatient interleukin- 2 in metastatic malignant melanoma. Cancer 1990; 65:2471–2477.

    Article  PubMed  CAS  Google Scholar 

  97. Foon KA, Smalley RV, Riggs CW, et al. The role of immunotherapy in acute myelogenous leukemia. Am Arch Intern Med 1983; 143: 1726–1731.

    Article  CAS  Google Scholar 

  98. Foon KA, Bottino GC, Abrams PG, et al. Phase II trial recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 1985; 78:216–220.

    Article  PubMed  CAS  Google Scholar 

  99. Foon KA, Doroshow J, Bonnem E, et al. A prospective randomized trial of alpha-2b-interferon/gamma interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Modif 1988; 7: 540–545.

    CAS  Google Scholar 

  100. Foon KA, Sherwin SA, Abrams PG, et al. Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med 1984; 311: 1148–1152.

    Article  PubMed  CAS  Google Scholar 

  101. Foon KA, Schroff RW, Bunn PA, et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 1984; 64(5) 1085–1093.

    PubMed  CAS  Google Scholar 

  102. Foon-KA, Maluish AE, Abrams PG. Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia: therapeutic and immunologic results. Am J Med 1986; 80: 351–356.

    Article  PubMed  CAS  Google Scholar 

  103. Freedman RS, Gutterman JU, Wharton JT, Rutledge RN. Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma. J Biol Response Modif 1983; 2: 133–138.

    CAS  Google Scholar 

  104. Fujisawa T, Waldman SR, Yonemoto RH. Leukocyte adherence inhibition by soluble tumor antigens and breast cancer patients. Cancer 1977; 39: 506–513.

    Article  PubMed  CAS  Google Scholar 

  105. Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer; a report from the Lung Cancer Study Group. Cancer 1984; 54: 1802–1813.

    Article  PubMed  CAS  Google Scholar 

  106. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921–930.

    Article  PubMed  CAS  Google Scholar 

  107. Glennie J, et al. Emergents of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of anti-idiotypic antibody and saporin. J Exp Med 1987; 166:43–62,

    Article  PubMed  CAS  Google Scholar 

  108. Goldberg R, Silgals R, Ayoob M, et al. A phase II trial of lymphoblastoid interferon (IF) in malignant melanoma. Proc ASCO 1984; 3:49.

    Google Scholar 

  109. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131 -labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9: 548–564.

    PubMed  CAS  Google Scholar 

  110. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J of Med 1993; 94: 297–312.

    Article  CAS  Google Scholar 

  111. Goldenberg DM, DeLand FH. History and status of tumor imaging with radiolabeled antibodies. J Biol Response Modif 1982 1: 121–136.

    Google Scholar 

  112. Golomb HM, Ratain MJ, Fefer A, et al. Randomized study of the duration of treatment with interferon alpha-2b in patients with hairy cell leukemia. J Natl Cancer Inst 1988; 80: 359–373.

    Google Scholar 

  113. Golomb HM. The treatment of hairy cell leukemia. Blood 1987; 69(4) 979–983.

    PubMed  CAS  Google Scholar 

  114. Goodman GE, Beaumier P, Hellstrom I, et al. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J Clin Oncol 1985; 3: 340–352.

    PubMed  CAS  Google Scholar 

  115. Goodman GE, Hellstrom I, Hummel D, et al. Phase I trial of monoclonal antibody MG-21 directed against a melanoma- associated GD3 ganglioside antigen. Proc ASCO 1987; 6: 209.

    Google Scholar 

  116. Goodman GE, Hellstrom I, Brodzinsky L, et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990; 8: 1083–1092.

    PubMed  CAS  Google Scholar 

  117. Grem JL, Jordan E, Robson ME, et al. Phase II study of fluorouracil, leucovorin and interferon-alfa-2a in metastatic colorectal carcinoma. J Clin Oncol 1993; 11: 1737–1745.

    PubMed  CAS  Google Scholar 

  118. Groopman JE. Therapeutic options and hairy cell leukemia. Semin Oncol 1985; 12() 5): 30–34.

    Google Scholar 

  119. Grossbard ML, Nadler LM. Immunotoxin therapy of malignancy, In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology pp 11–135. Philadelphia, JP Lippincott, 1992.

    Google Scholar 

  120. Grossbard ML, Freedman AS, Ritz J, et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion. Blood 1992; 79: 576.

    PubMed  CAS  Google Scholar 

  121. Grossbard ML, Lambert JM, Goldmacher VS, et al. Anti- B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11:726–737.

    PubMed  CAS  Google Scholar 

  122. Grossbard ML, Gribben JG, Freedman AS, et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin’s lymphoma. Blood 1993; 81: 2262–2271.

    Google Scholar 

  123. Grossbard ML, O’Day S, Gribben JG, et al. A phase II study of anti-B4-blocked ricin (Anti-B4-bR) therapy following autologous bone marrow transplantation (ABMT) for B-cell non-Hodgkin’s lymphoma. Proc ASCO 1994; 13:293.

    Google Scholar 

  124. Gundersen S, Flokkmann A. Interferon plus dacarbazine in advanced malignant melanoma: A phase I-II study. Eur J Cancer 1991; 27(2) 220–221.

    Article  PubMed  CAS  Google Scholar 

  125. Gutterman JU, Blumenschein GR, Alexanian R, et al. Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 1980; 93: 399–406.

    PubMed  CAS  Google Scholar 

  126. Hagenbeek A, VanHoof A, Conde P, et al. Interferon-alpha 2b vs control as maintenance therapy for low-grade non- Hodgkin’s lymphoma: Results from a prospective randomized clinical trial on behalf of the EORTC Lymphoma Cooperative Group. Proc ASCO 1995; 14: 386.

    Google Scholar 

  127. Hakes TB, Currie VE, Kaufman RG, et al. CMF +/- levamisole breast adjuvant chemotherapy: 5 year analysis. Proc ASCO 1982; 1:83.

    Google Scholar 

  128. Hale G, Clark MR, Marcus R, et al. Remission induction in non-Hodgkin’s lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; ii: 1394–1399.

    Article  Google Scholar 

  129. Halpern SE, Dillman RO. Radioimmunodetection with monoclonal antibodies against prostatic acid phosphatase. In: Winkler C, ed. Nuclear medicine in clinical oncology Berlin: Springer Verlag, Heidelberg, 1986: 164–170.

    Google Scholar 

  130. Hamblin TJ, Davies B, Sadullah S, et al. A Phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, interleukin-2 (IL- 2) and alfa-interferon (IFN). Proc ASCO 1991; 10: 294 (abstract).

    Google Scholar 

  131. Hanna MG Jr, Ransom JH, Pomato N, et al. Active specific immunotherapy of human colorectal carcinoma with an autologous tumor cell/bacillus calmette-guerin vaccine. Ann NY Acad Sci 1993; 690: 135–146.

    Article  PubMed  Google Scholar 

  132. Hawkins MJ. PPO Updates IL-2/LAK. Princ Prac Oncol 1989; 3(8): 1–14.

    Google Scholar 

  133. Henry DH, et al. Phase I clinical trial of Prosorba(tm) Protein A columns in malignancy: report on toxicity. Proc ASCO 1986; 5: 227.

    Google Scholar 

  134. Hersey P, Hasic E, MacDonald M, et al. Effects of recombinant leukocyte interferon (rIFN-aA) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer 1985; 51: (6): 815–826.

    Article  PubMed  CAS  Google Scholar 

  135. Hersey P, McLeod GRC, Thompson DB. Treatment of advanced malignant melanoma with recombinant interferon alpha 2a in combination with DTIC: long term follow-up of two phase II studies. Br J Haematol 1991; 79:60–66.

    Article  PubMed  Google Scholar 

  136. Hill NO, Pardue A, Khan A, et al. Interferon and cimetidine for malignant melanoma. N Engl J Med 1983; 308: 286.

    PubMed  CAS  Google Scholar 

  137. Hollinshead A, Arlen M, Yonemoto R, et al. Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunotherapy of malignant melanoma. Cancer 1982; 49: 1387.

    Article  PubMed  CAS  Google Scholar 

  138. Holohan TV, Phillips TM, Bowles C, Deissertroh A. Regression of canine mammary carcinoma after immunoadsorption therapy. Cancer Res 1982; 42: 3663–3668.

    PubMed  CAS  Google Scholar 

  139. Hoover HC Jr, Surdyke MG, Dangel RB, et al. Prospectively randomized trial of adjuvant active specific immunotherapy for human colorectal cancer. Cancer 1985; 55: 1236.

    Article  PubMed  Google Scholar 

  140. Houghton AN, Mintzer D, Cordon-Cardo C, et al. Mouse monoclonal antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985; 82:1242–1246.

    Article  PubMed  CAS  Google Scholar 

  141. Houghton AN, Scheinberg DA. Monoclonal antibodies: potential applications to the treatment of cancer. Semin Oncol 1986; 13(2) 165–179.

    PubMed  CAS  Google Scholar 

  142. Houghton A. Passive immunotherapy: monoclonal antibodies along as therapy (presentation). Williamsburg Conference, 1987.

    Google Scholar 

  143. Houghton A. Treatment of malignant melanoma with monoclonal antibodies (presentation). The significance of human response to monoclonal antibodies, Williamsburg Conference, 1987.

    Google Scholar 

  144. Ingram M, Sheldon CH, Jacques S. Development and preliminary clinical trial of immunotherapy for malignant glioma. J Biol Response Modif 1987; 6(5) 489–498.

    CAS  Google Scholar 

  145. John WJ, Neefe JR, Macdonald JS, et al. 5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer: results of two treatment schedules. Cancer 1993; 72: 191–195.

    Article  Google Scholar 

  146. Kaizer H, Levy R, Vorvall C. Autologous bone marrow transplantation in T-cell malignancies: a case report involving in vitro treatment of marrow with a pan T-cell of monoclonal antibody. J Biol Response Modif 1982; 1(3) 233–243.

    Google Scholar 

  147. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696–1711.

    PubMed  CAS  Google Scholar 

  148. Kavanagh JJ, Kudelka AP, Freedman R, et al. The amelioration of toxicity of intraperitoneal monoclonal Ab 90y-B72.3 with EDTA: A phase I study in refractory ovarian cancer. Proc Am Assoc Cancer Res 1993; 34: 223.

    Google Scholar 

  149. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: A concise update. Blood 1993; 82:691–703.

    PubMed  CAS  Google Scholar 

  150. Kantarjian HM, Smith TL, O’Brien S, et al. Prolonged survival following achievement of a cytogenetic response with alpha interferon therapy in chronic myelogenous leukemia. Ann Intern Med 1995; 122: 254–261.

    PubMed  CAS  Google Scholar 

  151. Kbalheim G, Funderud S, Kbaloy S. Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation. J Natl Cancer Inst 1988; 80(16) 1322–1325.

    Article  Google Scholar 

  152. Kelley VE, Fers W, Strom TB. Cloned human interferongamma, but not interferon-alpha or -beta, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol 1984; 132: 240–245.

    PubMed  CAS  Google Scholar 

  153. Kemeny N, Younes A. Alfa-2a interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience. Sem Oncol 1992; 19(2 suppl 3) 171–175.

    CAS  Google Scholar 

  154. Kempf RA, Grunberg SM, Daniels JR, et al. Recombinant interferon alpha-2 (Intron A) in a phase II study of renal cell carcinoma. J Biol Resp Modif 1986 ; 5(1) 27–35.

    CAS  Google Scholar 

  155. Khayat D, Borel C, Tourani JM. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993;12:2173–2180.

    Google Scholar 

  156. Kirkwood JM, Harris JE, Vera R, et al. A randomized study of low and high doses of leukocyte a-interferon in metastatic renal cell carcinoma: the American Cancer Society Collaborative Trial. Cancer Res 1985; 45: 863–871.

    PubMed  CAS  Google Scholar 

  157. Kirkwood JM, Ernstoff MS, Davis CA, et al. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Int Med 1985;103:32–36.

    PubMed  CAS  Google Scholar 

  158. Kirkwood JM, Ernstoff M. Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol 1986; 13(32): 48–56.

    PubMed  CAS  Google Scholar 

  159. Kirkwood JM, Ernstoff MS, Giuliano AE, et al. Interferon a-2a and dacarbazine in melanoma. J Natl Cancer Inst 1990; 82: 1062–1063.

    Article  PubMed  CAS  Google Scholar 

  160. Klefstrom T, Holsti P, Grohn P, Heinonen E. Combination of levamisole immunotherapy with conventional treatments in breast cancer. In: Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier North Holland, 1982: 187–194.

    Google Scholar 

  161. Kohn EC, Steis RG, Sausbille EA, et al. Phase II trial of intermittent high dose recombinant interferon alpha-2A and mycosis fungoides and the Sezary syndrome. J Clin Oncol 1990; 8: 155–160.

    PubMed  CAS  Google Scholar 

  162. Kokoschka EM, Micksche M. Active specific immunotherapy as adjuvant treatment for stage II malignant melanoma. Pigment Cell 1979; 5: 111.

    Google Scholar 

  163. Krigel RL, Padavic-Shaller KA, Rudolph AR, et al. Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta interferon. J Clin Oncol 1990; 8: 460–467.

    PubMed  CAS  Google Scholar 

  164. Krolick KA, Yaun D, Vitetta ES. Specific killing of a human breast carcinoma cell line by a monoclonal antibody coupled to the A-chain of ricin. Cancer Immunol Immunother 1981; 12: 39–41.

    Article  Google Scholar 

  165. Krown SE, Pinsky CM, Wanebo HJ, et al. Immunologic reactivity and prognosis in breast cancer. Cancer 1980; 46: 1746–1752.

    Article  PubMed  CAS  Google Scholar 

  166. Krown SE, Stoopler MB, Gralla RJ, et al. Phase II trial of human leukocyte interferon in non-small cell lung cancer: preliminary results. In: Jerry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier- North Holland, 1982: 397–405.

    Google Scholar 

  167. Krown SE. Interferons and interferon inducers in cancer treatment. Semin Oncol 1986; 13(2) 207–217.

    PubMed  CAS  Google Scholar 

  168. Krown SE, Real FX, Vadhan Raj S, et al. Kaposi’s sarcoma and the acquired immune deficiency syndrome: treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer 1986; 57(8 suppl) 1662– 1665.

    Article  PubMed  CAS  Google Scholar 

  169. Krown SE. The role of interferon in the therapy of epidemic Kaposi’s sarcoma. Semin Oncol 1987; 14(2 suppl 3): 27–33.

    PubMed  CAS  Google Scholar 

  170. Lacour J, Lacour F, Spira A, et al. Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomized trial. Br Med J 1984; 288: 589–592.

    Article  CAS  Google Scholar 

  171. Lacour J, Lacour F, Spira A, et al. Adjuvant immunotherapy with polyadenylic-polyuridylic acid in operable breast cancer. In: Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier North Holland, 1982: 183–187.

    Google Scholar 

  172. Lamm DL, Stogvill VD, Redwin HM. BCG immunotherapy of transitional cell carcinoma of the bladder. Proc ASCO 1983; 2: 55.

    Google Scholar 

  173. Larson SM, Carrasquillo JA, Krohn KA. Radiotherapy with ’anti-p97’ iodinated monoclonal antibodies in melanoma. In: Raymond C, ed. Proc World Congr Nuclear Medicine and Biology. New York: Pergamon Press, 1982: 3666–3669.

    Google Scholar 

  174. Larson SM, Carasquillo JA, Krohn KA, et al. Localization of p97 specific Fab fragments in human melanoma as a basis for immunotherapy. J Clin Invest 1983; 72: 2101–2114.

    Article  PubMed  CAS  Google Scholar 

  175. Lashford LS, Davies AG, Richardson RV, et al. A pilot study of 1-131 monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 1988; 61: 857–868.

    Article  PubMed  CAS  Google Scholar 

  176. Laszlo J, Hood L, Cox E, Goodwin V. A randomized trial of low doses of alpha interferon in patients with breast cancer. J Biol Resp Modif 1986 ; 5:206–210.

    CAS  Google Scholar 

  177. Lee KH, Talpaz M, Rothberg JM, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2 A in cancer patients: a phase I study. J Clin Oncol 1989; 7(11) 1726–1732.

    PubMed  CAS  Google Scholar 

  178. Legha SS, Papadopoulos NEJ, Plager C, et al. Clinical evaluation of recombinant interferon alfa-2a (roferon-a) in metastatic melanoma using two different schedules. J Clin Oncol 1987; 5: 1240–1246.

    PubMed  CAS  Google Scholar 

  179. Legha S, Plager C, Ring S, et al. A phase II study of biochemotherapy using interleukin-2 (IL-2) + interferon alfa 2A (IFN) in combination with cisplatin (C) Vinblastine (V) and DTIC (D) in patients with metastatic melanoma. Proc ASCO 1992; 11: 343 (abstract) and 1179 (abstract).

    Google Scholar 

  180. Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989; 16: 34–44.

    PubMed  CAS  Google Scholar 

  181. Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alpha and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993; 20 (suppl 9): 27–32.

    PubMed  CAS  Google Scholar 

  182. LeMaistre C, Rosenblum MG, Reuben JM, et al. Therapeutic effects of genetically engineered toxin (DAB486- IL-2) in patients with chronic lymphocytic leukemia. Lancet 1991; 337: 1124.

    Article  PubMed  CAS  Google Scholar 

  183. Lemkin S, Tokita K, Sherman G. Phase I-II study of monoclonal antibodies (MCA) in gastrointestinal cancer. Proc ASCO 1984; 3:47.

    Google Scholar 

  184. Lenhard RE, Order SE, Spunberg JJ, et al. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin’s disease. J Clin Oncol 1985; 3: 1296–1300.

    PubMed  Google Scholar 

  185. Lentz MR. Continuous whole blood ultrapheresis procedure in patients with metastatic cancer. J Biol Resp Modif 1989; 8(5) 511–527.

    CAS  Google Scholar 

  186. Lichtenstein A, Spina C, Berek JS, et al. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity. Cancer Res 1988; 48: 5853–5859.

    PubMed  CAS  Google Scholar 

  187. Lichtin A, Iliopoulos D, Guerry D. Therapy of melanoma with an anti-melanoma ganglioside monoclonal antibody (a possible mechanism of a complete response). Proc ASCO 1988; 7: 247.

    Google Scholar 

  188. Lipton A, Harvey HA, Simmonds MA, et al. Lack of enhanced activity of systemic interferon by cimetidine in malignant melanoma. Proc ASCO Oncol 1984; 3: 56.

    Google Scholar 

  189. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified Gm2 ganglioside. Cancer Res 1989; 49: 7045–7050.

    PubMed  CAS  Google Scholar 

  190. LoBuglio AF, Khazaeli MV, Lee J, et al. Pharmacokinetics and immune response to XOMAZYME-MEL in melanoma patients. Antibody Immunoconj Radiopharm 1988; 1(4) 305–310.

    Google Scholar 

  191. LoBuglio AF, Wheeler R, Leavitt RD, et al. Pharmacokinetics and immune response to chimeric mouse/human monoclonal antibody (CHI7-1 A) in man (Abstr). Proc ASCO 1988; 7: 111.

    Google Scholar 

  192. Logothetis CJ, Hossan E, Sella A, et al. Fluorouracil and recombinant human interferon alpha-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer Inst 1991; 83: 285–288.

    Article  PubMed  CAS  Google Scholar 

  193. Lotze MT, Carrasquillo JA, Weinstein JN, et al. Monoclonal antibody imaging of human melanoma. Radioimmunodetection by subcutaneous or system injection. Ann Surg 1986; 204: 223–235.

    Article  PubMed  CAS  Google Scholar 

  194. Mackenson A, Ferradini L, Carcelain G, et al. Evidence for in situ amplification of cytolytic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 1993; 53: 3569–3573.

    Google Scholar 

  195. Mackenson A, Carcelain G, Viels S, et al. Direct evidence to support the immunosurveillance concept in a regressive melanoma. J Clin Invest 1994; 93: 1397–1402.

    Article  Google Scholar 

  196. Mahaley M, Urso M, Whaley R. Malignant glioma treatment with interferon. Proc ASCO 1984; 3: 65.

    Google Scholar 

  197. Mandell F, Tribalto M, Cantonetti M, et al. Recombinant alpha-2b interferon as maintenance therapy in responding multiple myeloma patients. Blood 1987; 70(suppl 1): 247a.

    Google Scholar 

  198. Marshall ME, Simpson W, Butler K, et al. Treatment of renal cell carcinoma with daily low-dose alpha-interferon. J Biol Resp Mod 1989; 8: 453–461.

    CAS  Google Scholar 

  199. Martin A, Nerenstone S, Urba WJ, et al. Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study. J Clin Oncol 1990; 8: 721–730.

    PubMed  CAS  Google Scholar 

  200. Mathé G, Amiel JL, Schwarzenberg L, et al. Active immunotherapy for acute lymphoblastic leukemia. Lancet 1969; 1:697–699.

    Article  PubMed  Google Scholar 

  201. Mattson K, Holsti LR, Niiranen A. et al. Human leukocyte interferon as part of a combined treatment for previously untreated small cell lung cancer. J Biol Resp Modif 1985; 4(1) 8–17.

    CAS  Google Scholar 

  202. McCabe MS, Stablein D, Hawkins MJ. The modified group C experience-phase III randomized trials of IL-2 vs IL-2/LAK in advanced renal cell carcinoma and advanced melanoma. Proc ASCO 1991; 10: 213 (abstract).

    Google Scholar 

  203. McCulloch PB, Poon M, Dent PB, Dawson P.A stratified randomized trial of 5-fluorouracil, doxorubicin (Adriamycin) and cyclophosphamide alone or with BCG in stage IV breast cancer. In: Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier North Holland, 1982: 183–186.

    Google Scholar 

  204. McCune CS, Schapira DV, Henshaw EC. Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 1981; 47: 1984–1987.

    Article  PubMed  CAS  Google Scholar 

  205. McLaughlin P, Cabanillias F, Hagemeister F, et al. CHOPBleo plus interferon for stage IV low-grade lymphoma. Am J Oncol 1993; 4: 205–211.

    CAS  Google Scholar 

  206. McKneally MF, Maver C, Kausel HW, Alley RD. Regional immunotherapy with intrapleural BCG for lung cancer. J Thorac Cardiovasc Surg 1976; 72: 333.

    PubMed  CAS  Google Scholar 

  207. Melino G, Elliott P, Cooke KB, et al. Allogeneic antibodies (Abs) for drug targeting to human neuroblastoma. (Nb). Proc ASCO 1984; 3: 47.

    Google Scholar 

  208. Mellstedt H, Frodin JE, Masucci G. Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma. Oncology 1989; 25-32.

    Google Scholar 

  209. Miller RA, Maloney DJ, McKillop J, et al. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 1981; 68: 78–86.

    Google Scholar 

  210. Miller RA, Levy R. Response of cutaneous B-cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 1981; 2: 226–230.

    Article  PubMed  CAS  Google Scholar 

  211. Miller RA, Maloney DJ, Warnke R, et al. Treatment of Bcell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306: 517–522.

    Article  PubMed  CAS  Google Scholar 

  212. Moertel CG, Rubin J, Kbols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 1989;7:865–868.

    PubMed  CAS  Google Scholar 

  213. Moertel CG, Reitemeier RJ. Advances in Gastrointestinal Cancer: Clinical Management and Chemotherapy. New York, NY, Harper and Row, 1989: 86–107.

    Google Scholar 

  214. Molinolo A, Simpson JF, Thor A, Schlom J. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 1990; 50: 1291–1298.

    PubMed  CAS  Google Scholar 

  215. Moormeier JA, Ratain MJ, Westbrook CA, et al. Lowdose interferon alpha-2b in the treatment of hairy cell leukemia. J Natl Cancer Inst 1989; 81: 1172–1174.

    Article  PubMed  CAS  Google Scholar 

  216. Morales A, Ersil A. Adjuvant BCG immunotherapy in the prophylaxis and treatment of non-invasive bladder cancer. In: Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier North Holland, 1982: 301–307.

    Google Scholar 

  217. Morton D, Hoon D, Nizze J, et al. Polyvalent vaccine improves survival of patients with metastatic melanoma. Ann Surg 1992; 216(4) 463–482.

    Article  PubMed  CAS  Google Scholar 

  218. Morton DL. Active immunotherapy against cancer: present status. Semin Oncol 1986; 13(2) 180–185.

    PubMed  CAS  Google Scholar 

  219. Moseley R, Zalutsky MR, Coakham HB, et al. Distribution of 1-131 81C6 monoclonal antibody administered via carotid artery in patients with glioma. J Nucl Med 1987; 28(4) 603–604.

    Google Scholar 

  220. Mulder NH, deVries EGE, Sleifjer DTh, et al. Dacarbazine (dtic), human recombinant interferon alpha 2a (roferon) and 5-fluorouracil for disseminated malignant melanoma. Br J Cancer 1992; 65: 303–304.

    Article  PubMed  CAS  Google Scholar 

  221. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol 1987; 14 (Suppl2) 36–42.

    PubMed  CAS  Google Scholar 

  222. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with dna-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307–11311.

    Article  PubMed  CAS  Google Scholar 

  223. Nagai M, Watanabe K. Treatment of malignant brain tumors with interferons - special reference to the combination therapy and maintenance therapy. J Interferon Res 1988; 8: S21.

    Google Scholar 

  224. Namba M, Miyoshi T, Kanamori T, et al. Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture. Jpn J Cancer Res 1982; 73:819–824.

    CAS  Google Scholar 

  225. Neefe JR, Silgals R, Ayoob M, Schein PS. Minimal activity of recombinant clone A interferon in metastatic colon cancer. J Biol Resp Modif 1984; 3(4) 366–370.

    CAS  Google Scholar 

  226. Neidhart JA, Murphy SG, Hennick LA, Wise HA. Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer 1980; 46: 1128–1134.

    Article  PubMed  CAS  Google Scholar 

  227. Neidhart JA. Interferon therapy for the treatment of renal cancer. Cancer 1986; 57: 1696–1699.

    Article  PubMed  CAS  Google Scholar 

  228. Niederle N, Doberauer C, Kloke O. Treatment of chronic myelogenous leukemia with recombinant interferonalpha (IFN-2b). Proc ASCO 1986; 5:236.

    Google Scholar 

  229. Oberg K, Norheim I, Lind E. Treatment of malignant carcinoid tumors with human leukocyte interferon: long term results. Cancer Treat Rep 1986; 70(11) 1297–1304.

    PubMed  CAS  Google Scholar 

  230. O’Connell MJ, Colgan JP, Oken MM, et al. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukemia: an Eastern Cooperative Oncology Group Pilot Study. J Clin Oncol 1986; 4: 128–136.

    PubMed  Google Scholar 

  231. Ohno R, Kimura K. Treatment of multiple myeloma with recombinant interferon alpha-2a. Cancer 1986; 57: 1685–1688.

    Article  PubMed  CAS  Google Scholar 

  232. Oldham RK. Monoclonal antibodies in cancer therapy. J Clin Oncol 1983; 1(9) 582–590.

    PubMed  CAS  Google Scholar 

  233. Oldham RK. Antibody-drug and antibody toxin conjugates. In: Reif AE, Mitchell MS, eds. Immunity to cancer. New York: Academic Press, 1985: 575–586.

    Google Scholar 

  234. Oldham RK. Biologicals for cancer treatment: interferons. Hosp Pract 1985; 20: 72–91.

    Google Scholar 

  235. Oldham RK, ed. Symposium on ex vivo plasma immunoabsorption and protein A in cancer therapy. J Biol Resp Modif 1984; 3(3) 229–230.

    Google Scholar 

  236. Oldham RK, Foon KA, Morgan AC, et al. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 1984; 2(11) 1235–1244.

    PubMed  CAS  Google Scholar 

  237. Oldham RK, Smalley RV The role of interferon in the treatment of cancer. In: Zoon KC, Noguchi PC, Lui TY, eds. Interferon: research, clinical application, and regulatory consideration. Amsterdam: Elsevier Science, 1984: 191–205.

    Google Scholar 

  238. Oldham RK, Lewis M, Orr DW, et al. Adriamycin customtailored immunoconjugates in the treatment of human malignancies. Mol Biother 1988; 1(2) 103–113.

    PubMed  CAS  Google Scholar 

  239. Orr DW, Oldham RK, Lewis M, et al. Phase I trial of mitomycin-c immunoconjugate cocktails in human malignancies. Mol Biother 1989; 1(4) 229–240.

    PubMed  CAS  Google Scholar 

  240. Oldham RK. Custom tailored drug immunoconjugates in cancer therapy. Mol Biother 1991; (3) 148–162.

    PubMed  CAS  Google Scholar 

  241. Oldham RK. Cancer cures: by the people, for the people at what cost? Mol Biother 1990; 2(1) 2–3.

    PubMed  CAS  Google Scholar 

  242. Oldham RK. IL-2 activated tumor derived activated cells. In: Hiddleman, ed. Oncologic dialogue, 1990.

    Google Scholar 

  243. Oldham RK. Monoclonal antibody therapy. In: Chiao JW, ed. Biological response modifiers and cancer research, vol. 40. New York: Marcel Dekker, 1988: 3–16.

    Google Scholar 

  244. Oldham RK, Bartal AH, Yannelli JR, et al. Intra-arterial and intracavitary administration with advanced cancer: feasibility and laboratory results. Proc AACR 1988.

    Google Scholar 

  245. Oldham RK. Biologicals and biological response modifiers: the design of clinical trials. J Biol Resp Modif 1985; 4: 117–128.

    CAS  Google Scholar 

  246. Oldham RK. Monoclonal antibodies. In: Nathanson L, ed. Management of advanced melanoma. Contemporary issues in clinical oncology. New York: Churchill Livingstone, 1986: 195–207.

    Google Scholar 

  247. Oldham RK. Patients as research partners. In: The privatization of cancer research. City Club of Cleveland, Cleveland, OH. Vital speeches of the day. October 1, 1987:763-766.

    Google Scholar 

  248. Oldham RK. Interferon treatment of non-Hodgkin’s lymphoma and myeloma: a model for biotherapy. In: Revel M, ed. Clinical aspects of interferons. Boston: Kluwer Academia, 1988: 109–120.

    Chapter  Google Scholar 

  249. Oldham RK, Maleckar JR, Friddell CS, et al. Tumorderived activated cells: preliminary laboratory and clinical results. Clin Chem 1989; 35(8) 1576–1580.

    PubMed  CAS  Google Scholar 

  250. Oldham RK, Dillman RO, Yannelli JR, et al. Continuous infusion interleukin-2 and tumor derived activated cells as treatment of advanced solid tumors: An NBSG trial. Molecular Biotherapy 1991; 3(2) 68–73.

    PubMed  CAS  Google Scholar 

  251. Oldham RK, Lewko W, Good R, et al. Growth of tumor derived activated T cells for the treatment of cancer. Cancer Biotherapy 1994; 9(3) 211–224.

    Article  PubMed  Google Scholar 

  252. Oliver RTD, Mehta A, Miller RM, Barnett MJ. Unexplained spontaneous regression of renal cell carcinoma. J Biol Resp Modif 1981.

    Google Scholar 

  253. Oratz et al. Society for Biological Therapy meeting, Berkeley, CA; November 1988.

    Google Scholar 

  254. Order SE, Stillwagon GB, Klein JL, et al. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group Study. J Clin Oncol 1985; 3(12): 1573-1582.

    PubMed  CAS  Google Scholar 

  255. Paciucci PA, Holland JF, Glidewell O, et al. Recombinant interleukin-2 continuous infusion and adoptive transfer of recombinant interleukin-2 activated cells in patients with advanced cancer. JCO 1989; 7: 869–878.

    CAS  Google Scholar 

  256. Papadopoulos NEJ, Howard JG, Murray JL. Phase II DTIC and interleukin 2 (IL-2) trial for metastatic malignant melanoma. Proc Am Soc Clin Oncol 1990; 9: 277 (abstract).

    Google Scholar 

  257. Paque RE. RNA as a biological response modifier: a reassessment. J Biol Resp Modif 1983; 2: 563–576.

    CAS  Google Scholar 

  258. Parkinson DR, Abrams JS, Wiernik PH. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol 1990; 8: 1650–1656.

    PubMed  CAS  Google Scholar 

  259. Pazdur R, Bready B, Moore DF Jr. Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas. Semin Oncol 1991; 18 (Suppl7) 67–70.

    PubMed  CAS  Google Scholar 

  260. Pazdur R, Moore DF Jr, Bready B. Modulation of fluorouracil with recombinant alfa interferon: M.D. Anderson Clinical Trial. Semin Oncol 1992; 19 (Suppl3) 176–179.

    PubMed  CAS  Google Scholar 

  261. Peterson BA, O M, Ozer H, et al. Cyclophosphamide vs cyclophosphamide and interferon alpha 2b in follicular low grade lymphoma: A preliminary report of an intergroup trial (CAL GB 869 & EST 7486) Proc ASCO 1993; 12: 1240–1241.

    Google Scholar 

  262. Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419–1426.

    PubMed  CAS  Google Scholar 

  263. Pinsky C, Camcko F, Kerr D, et al. Treatment of superficial bladder cancer with intravesical BCG. Proc ASCO 1983; 2: 57.

    Google Scholar 

  264. Poon MA, O’Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–1418.

    PubMed  CAS  Google Scholar 

  265. Prager MD, Baechtel FS, Peters PC, et al. Specific immunotherapy of human metastatic renal cell carcinoma. Proc AACR 1981; 22: 163.

    Google Scholar 

  266. Press O, Applebaum F, Ledbetter J. Serotherapy of malignant B-cell lymphomas with monoclonal antibody 1F5 (anti-CD20). Proc ASCO 1986; 5:221.

    Google Scholar 

  267. Press O, Applebaum F, Ledbetter J. Serotherapy of malignant B-cell lymphomas with monoclonal antibody 1F5 (anti-CD20) Proc ASCO 1986; 5:221.

    Google Scholar 

  268. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeledantibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219–1224 and 1265-1268.

    Article  PubMed  CAS  Google Scholar 

  269. Price CG, Rohatiner A, Lister TA, et al. Interferon-alpha 2b in addition to chlorambucil in the treatment of follicular lymphoma: Preliminary results of a randomized trial. Eur J Cancer 1991; 27(4) S34–36.

    PubMed  Google Scholar 

  270. Punt CJ, Burhouts JT, Croles JJ, et al. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A multicenter phase II study. Cancer 1993; 72: 2107–2111.

    Article  PubMed  CAS  Google Scholar 

  271. Pyrhonen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1993; 10: 1919–1926.

    Google Scholar 

  272. Quesada JR, Alexanian R, Hawkins M, et al. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 1986; 67: 275–278.

    PubMed  CAS  Google Scholar 

  273. Quesada JR, Evans L, Saks SR, Gutterman JU. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma. J Biol Resp Modif 1988,7; 234–239.

    CAS  Google Scholar 

  274. Quesada JR, Kurzrock R, Sherwin SA, et al. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Resp Modif 1987; 6: 20–27.

    CAS  Google Scholar 

  275. Quesada JR, Swanson DA, Trindade A, Gutterman JR. Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 1983; 43: 940–947.

    PubMed  CAS  Google Scholar 

  276. Quesada JR, Rio A, Swanson D, et al. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma . J Clin Oncol 1985; 3(11) 1522–1528.

    PubMed  CAS  Google Scholar 

  277. Quesada JR, Reuben JR, Manning JT, et al. Alpha interferon for the induction of remission in hairy cell leukemia. N Engl J Med 1984; 310: 15–18.

    Article  PubMed  CAS  Google Scholar 

  278. Quesada JR, Gutterman JU, Hersh EM. Treatment of hairy cell leukemia with alpha interferons. Cancer 1986; 57: 1678–1680.

    Article  PubMed  CAS  Google Scholar 

  279. Ralph P, Harris PE, Punjabi CG, et al. Lymphokine and using ‘terminal’ differentiation of the human monoblast leukemia line U937: a role for gamma interferon. Blood 1983;62: 1169–1175.

    PubMed  CAS  Google Scholar 

  280. Ratain MJ, Vardiman JW, Golomv HM. The role of interferon and the treatment of hairy cel l leukemia. Semin Oncol 1986; 13(32): 21–28.

    PubMed  CAS  Google Scholar 

  281. Rauschmeier HA. Immunotherapy of metastatic renal cancer. Semin Surg Oncol 1988; 4: 169–173.

    Article  PubMed  CAS  Google Scholar 

  282. Ray PK, Raychaudhuri S, Allen P. Mechanism of regression of mammary adenocarcinomas in rats following plasma absorption over protein A-containing Staphylococcus aureus. Cancer Res 1982; 42:4970–4974.

    PubMed  CAS  Google Scholar 

  283. Real FX, Bander NH, Yeh S, et al. Monoclonal antibody F23: radiolocalization in phase I study in patients with renal cell carcinoma. Proc ASCO 1987; 6: 240.

    Google Scholar 

  284. Reily RM. Immunoscintigraphy of tumours using 99Tcm-labelled monoclonal antibodies: a review. Nucl Med Commun 1993; 14: 347–359.

    Article  Google Scholar 

  285. Retsas S, Preistman TJ, Newton KA, et al. Evaluation of human lymphoblastoid interferon in advanced malignant melanoma. Cancer 1983; 51: 273–276.

    Article  PubMed  CAS  Google Scholar 

  286. Richards JM, Mehta N, Ramming K, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 8: 1338–1343.

    Google Scholar 

  287. Richards JM, Mehta N, Schroeder L. Sequential chemotherapy/immunotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 1992; 11: 346 (abstract).

    Google Scholar 

  288. Richner J, Joss RA, Goldhirsch A, Brunner KW. Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma. Eur J Cancer 1992; 28A: 1044–1047.

    Article  PubMed  CAS  Google Scholar 

  289. Riechman L, Clark MR, Waldmann H, Winter G. Reshaping human antibodies with therapy. Nature 1989; 332: 323–327.

    Article  Google Scholar 

  290. Rinehart JJ, Malspeis L, Young D, Neidhart JA. Phase I/II trial of human recombinant interferon gamma and renal cell carcinoma. J Biol Resp Modif 1986; 5(4) 300–308.

    CAS  Google Scholar 

  291. Ritz J, Pesando JM, Sallan SE, et al. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 1981; 58: 141–152.

    PubMed  CAS  Google Scholar 

  292. Ritz J, Schlossman SE Utilization of monoclonal antibodies in treatment of leukemia and lymphoma. Blood 1982; 59: 1–11.

    PubMed  CAS  Google Scholar 

  293. Robinson WA, Mughal TI, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiol 1986; 172: 275–282.

    CAS  Google Scholar 

  294. Rohatiner AZS, Balkwill FR, Malpas JS, et al. Experience with human lymphoblastoid interferon and acute myelogenous leukemia (AML). Cancer Chemother Pharmacol 1983; 11:56–58.

    Article  PubMed  CAS  Google Scholar 

  295. Rojas AF, Firestein JN, Mickiewicz E, et al. Levamisole in advanced breast cancer. Lancet 1976; 1:211–215.

    Article  PubMed  CAS  Google Scholar 

  296. Rosen ST, Zimmer AM, Goldman-Leikin R, et al. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphoma using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 1987; 5(4) 562–573.

    PubMed  CAS  Google Scholar 

  297. Rosenberg SA. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2. Semin Oncol 1986; 13(2) 200–206.

    PubMed  CAS  Google Scholar 

  298. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine- activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313(23) 1485–1492.

    Article  PubMed  CAS  Google Scholar 

  299. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, special report. N Engl J Med 1988; 319: 1676–1680.

    Article  PubMed  CAS  Google Scholar 

  300. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 17(12) 1863–1874.

    Google Scholar 

  301. Rosenberg SA, Lotze MT, Yang JC. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–485.

    Article  PubMed  CAS  Google Scholar 

  302. Rosenberg SA, Lotze MT, Yang JC. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85: 622–632.

    Article  PubMed  CAS  Google Scholar 

  303. Rosenberg SA, Aebersold P, Cornetta K. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. NEJM 1990; 323: 570–578.

    Article  PubMed  CAS  Google Scholar 

  304. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992; 10: 180–199.

    PubMed  CAS  Google Scholar 

  305. Rubin SC. Monoclonal antibodies in the management of ovarian cancer. Cancer 1993; 71(4 suppl) 1602–1612.

    Article  PubMed  CAS  Google Scholar 

  306. Rubio ED, Jimeno J, Camps C, et al. Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: Activity in liver metastasis. Cancer Invest 1992; 10: 259–264.

    Article  Google Scholar 

  307. Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improved survival in lung cancer. N Engl J Med 1972; 287: 1013.

    Article  PubMed  CAS  Google Scholar 

  308. Rudczynski AB, Dyer CA, Mortensen RF. Detection of cell-mediated immune reactivity of breast cancer patients by the leukocyte adherence inhibition response to MCF-7 extracts. Cancer Res 1978; 38: 3590–3594.

    PubMed  CAS  Google Scholar 

  309. Sarna J, Figlin R, Callaghan M. Alpha (human leukocyte)- interferon as treatment for non-small cell carcinoma of the lung: a phase II trial. J Biol Resp Modif 1983; 2(4) 343–347.

    CAS  Google Scholar 

  310. Scadden DT, Doweiko J, Schenkein D, et al. A Phase I/II trial of combined immunoconjugate and chemotherapy for AIDS-related lymphoma. Blood 1993; 82(suppl 1): 386a.

    Google Scholar 

  311. Schlom J, Wunderlich D, Teramoto YA. Generation of human monoclonal antibodies reactive with human mammary carcinoma cells. Proc-Natl Acad Sci USA 1980; 77: 6841–6845.

    Article  PubMed  CAS  Google Scholar 

  312. Schnall SF, Davis C, Ziyadeh T, et al. Treatment of metastatic renal cell carcinoma (RCC) with intramuscular (IM) recombinant interferon alpha (alFN, Hoffman- LaRoche). Proc ASCO 1986; 5: 227.

    Google Scholar 

  313. Schofield JR, Robinson WA, Murphy JR, et al. Low doses of interferon-a are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994; 121: 736–744.

    PubMed  CAS  Google Scholar 

  314. Schroff RW, Woodhouse CS, Foon KA, et al. Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 25OK dalton melanoma associated antigen. J Natl Cancer Inst 1985; 74: 299–306.

    PubMed  CAS  Google Scholar 

  315. Schrof RW, Morgan AC Jr, Woodhouse CS, et al. Monoclonal antibody therapy in malignant melanoma: factors effecting in vivo localization. J Biol Resp Modif 1987; 6: 457–472.

    Google Scholar 

  316. Schulof RS, Lloyd MJ, Ueno WM, et al. Phase II trial of thymosin fraction 5 in advanced renal cancer. J Biol Resp Modif 1984; 3: 151–159.

    CAS  Google Scholar 

  317. Scorticatti CH, DeLaPena NC, Vellora OG, et al. Systemic interferon IFN-alpha treatment of multiple bladder papilloma grade I or II patients: pilot study. J Interferon Res 1982; 2: 339–343.

    Article  PubMed  CAS  Google Scholar 

  318. Sears HF, Herlyn D, Steplewski Z, Kropowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Resp Modif 1984; 3: 138–150.

    CAS  Google Scholar 

  319. Sears HF, Atkinson B, Mattis J, et al. Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumors. Lancet 1982; 1: 762–765.

    Article  PubMed  CAS  Google Scholar 

  320. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45:5910–5913.

    PubMed  CAS  Google Scholar 

  321. Serrou B, Sancho-Garnier H, Cappelaere P, et al. Inefficacy of post radiotherapeutic BCG immunotherapy in T3-T4 breast cancer patients: a randomized trial. In: Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier North Holland, 1982: 195–198.

    Google Scholar 

  322. Sertoli MR, Bernengo MG, Ardizzoni A, et al. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology 1989; 46: 96–98.

    Article  PubMed  CAS  Google Scholar 

  323. Sertoli MR, Quierolo P, Bajetta E. Dacarbazine (DTIC) with or without recombinant interferon alpha 2a at different dosages in the treatment of stage IV melanoma patient: preliminary results of a randomized trial. Proc ASCO 1992; 11: 345 (abstract).

    Google Scholar 

  324. Sher H, Chapman R, Shack B, et al. Combination chemotherapy and radiotherapy with and without thymosin in small cell lung cancer. Proc Third World Conf on Lung Cancer, Abstr, Jpn, 1982: 155.

    Google Scholar 

  325. Sherwin SA, Mayer D, Ochs J J, et al. Recombinant leukocyte A interferon in advanced breast cancer. Ann Intern Med 1983; 98: 598–602.

    PubMed  CAS  Google Scholar 

  326. Slater DE, Krown SE, Pinsky CM, et al. Human leukocyte (alpha) interferon (HuIFN-(Le)) and cimetidine in malignant melanoma. Proc ASCO 1984; 3: 54.

    Google Scholar 

  327. Smalley RV, Bartolucci AA, Moore MA, et al. Southeastern Cancer Study Group Breast Cancer Studies 1971-1981 .Int J Rad Oncol Biol Phys 1983; 9: 1867–1874.

    CAS  Google Scholar 

  328. Smalley R, Andersen J, et al. Interferon-alpha combined with cytotoxic chemotherapy for patients with non- Hodgkin’s lymphoma. N Engl J Med 1984; 311: 1148.

    Article  Google Scholar 

  329. Solal-Celigney P. Recombinant interleukin alpha 2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d’Etude des Lymphomes l’Adulte. N Engl J Med 1993; 329: 1108–1114.

    Article  Google Scholar 

  330. Sosman JA, Hank JA, Sondel PM. In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies. Semin Oncol 1990; 17(1) 22–30.

    PubMed  CAS  Google Scholar 

  331. Sparano JA, Fisher RI, Sunderland M. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alpha 2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969–1977.

    PubMed  CAS  Google Scholar 

  332. Spitler LE, Wussow P, Carey RW, et al. Phase II trial of a monoclonal antimelanoma antibody ricin a chain immunotoxin in therapy of malignant melanoma. J Clin Oncol 1990.

    Google Scholar 

  333. Springer GF, Murphy S, Desai PR, Scanlon EF. Breast cancer patient’s cell-mediated immune response to Thomsen-Friedenreich (T) antigen. Cancer 1980; 45: 2949–2954.

    Article  PubMed  CAS  Google Scholar 

  334. Steis RG, Carrasquillo JA, McCabe R, et al. Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 1990; 8: 476–490.

    PubMed  CAS  Google Scholar 

  335. Steele G Jr, Wang BS, Richie GP, et al. Results of xenogeneic I-RNA therapy in patients with metastatic renal cell carcinoma. Cancer 1981; 47: 1286–1288.

    Article  PubMed  Google Scholar 

  336. Steffens TA, Bajorin DF, Williams LJ, et al. A phase I trial of R24 monoclonal antibody and recombinant human macrophage colony stimulating factor (rhM-CSF) in patients with advanced melanoma. Proc ASCO 1992; 1182: 344(abstract).

    Google Scholar 

  337. Stein R, Chen S, Sharkey RM, Goldenberg DM. Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting. Cancer Res 1990; 50: 1330–1336.

    PubMed  CAS  Google Scholar 

  338. Steiner A, Wolf C, Pehamberger H. Comparison of the effects of three different treatment regimens of recombinant interferons in disseminated malignant melanoma. J Cancer Res Clin Oncol 1987; 113: 459–465.

    Article  PubMed  CAS  Google Scholar 

  339. Stephens EGW, Wood HF, Mason V The influence of levamisole on the survival of patients with disseminated mammary carcinoma treated with chemotherapy. In: Terry WD, Rosenberg SA, eds. Immunotherapy of human cancer. New York: Elsevier North Holland, 1982: 199–204.

    Google Scholar 

  340. Stevenson HC, Ochs JJ, Halvorson L, et al. Recombinant alpha interferon in treatment of 2 patients with pulmonary lymphoma: dramatic responses with resolution of pulmonary complications. Am J Med 1984; 77: 355–358.

    Article  PubMed  CAS  Google Scholar 

  341. Stoter G, Aamdal S, Rodenhius S. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol 1991; 9: 1687–1691.

    PubMed  CAS  Google Scholar 

  342. Strander H, Canctell K, Jacobsson PA, et al. Exogenous interferon therapy in osteogenic sarcoma. Acta Orthop Scand 1974; 45:958.

    Google Scholar 

  343. Sukumar S, Zbar B, Tereta N, et al. Plasma therapy of primary rat mammary carcinoma: antitumor activity of tumor-bearer plasma adsorbed against inactivated CNBr sepharose or protein A-sepharose. J Biol Resp Modif 1984; 3(3) 303–315.

    CAS  Google Scholar 

  344. Takakura K. Effect of combined treatment with Interferon- B and chemoradiotherapy for malignant gliomas. J Interferon Res 1988; 8: S20(abstr).

    Google Scholar 

  345. Takita H. Effect of postoperative empyema in survival of patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg 1970; 59: 642.

    PubMed  CAS  Google Scholar 

  346. Talpas M, Kantarjian HM, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha-A in chronic myelogenous leukemia. N Engl J Med 1986; 314(17) 1065–1069.

    Article  Google Scholar 

  347. Talpaz M, Kantarjian HM, McCredie KB, et al. Clinical investigation of human alpha interferon and chronic myelogenous leukemia. Blood 1987; 69(5) 1280–1288.

    PubMed  CAS  Google Scholar 

  348. Tanaka F, Yonemoto RH, Waldman S. Blocking factors in sera of breast cancer patients. Cancer 1979; 43: 838–847.

    Article  PubMed  CAS  Google Scholar 

  349. Taylor-Papadimitriou J, Peterson JA, Arklie J, et al. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981; 28: 17–21.

    Article  PubMed  CAS  Google Scholar 

  350. Terman DS, Yamamoto T, Mattioli M, et al. Extensive necrosis of spontaneous canine mammary adenocarcinoma after extracorporeal perfusion over Staphylococcus aureas Cowans I. J Immunol 1980; 124: 795–805.

    PubMed  CAS  Google Scholar 

  351. Terman DS, Young JB, Shearer WT, et al. Preliminary observations of the effects on breast adenocarcinoma of plasma perfused over immobilized protein A.N Engl J Med 1981; 305: 1195–1200.

    Article  PubMed  CAS  Google Scholar 

  352. The Italian Cooperative Study Group on Chronic Myelogenous Leukemia: Interferon-oc2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820–825.

    Article  Google Scholar 

  353. Thompson D, Adena M, McLeod GRC. Interferon alpha 2a does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: results of a multi-institutional Australian randomized trial QMP8704. Proc ASCO 1992; 11: 343 (abstract).

    Google Scholar 

  354. Thompson JA, Shulman KL, Benyunes MC, et al. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992; 10(6) 960–968.

    PubMed  CAS  Google Scholar 

  355. Timms RM, Walker LE, Hirschowitz L, et al. Human lung cancer KSl/4-methotrexate phase I (abstr). In: Dillman RO, Royston I, eds. Proc 2nd Annual Int Conf on Monoclonal Antibody Immunoconjugates for Cancer. San Diego, 28,1987.

    Google Scholar 

  356. Torti FM, Lum BL. Superficial carcinoma of the bladder: natural history and the role of interferons. Semin Oncol 1986; 13(32): 57–60.

    PubMed  CAS  Google Scholar 

  357. Torti FM, Chotliffe LD, Williams RD, et al. Superficial bladder cancers are responsive to alpha 2 interferon administered intravesically. Proc ASCO 1984; 3: 160.

    Google Scholar 

  358. Tykka RF, Hjelt L, Orauisto KG, et al. Disappearance of lung metastases during immunotherapy in 5 patients suffering from renal carcinoma. Scand J Respir Dis 1974; 89: 123–134.

    CAS  Google Scholar 

  359. Uhr J, Monoclonal antibodies as carriers for toxins. Williamsburg Conference, November 1987.

    Google Scholar 

  360. Vadhan-Raj S, Cordon-Cardo C, Carswell E, et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol 1988; 6(10) 1636–1648.

    PubMed  CAS  Google Scholar 

  361. Van Der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–1647.

    Article  PubMed  Google Scholar 

  362. Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991; 51:4052–4058.

    PubMed  CAS  Google Scholar 

  363. West WH, Tauer KW, Orr DW, et al. Continuous infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer: results of a multi-centered trial. J Clin Oncol 1990.

    Google Scholar 

  364. Vessela RL, Chiou RK, Grund FM, et al. Renal cell carcinoma (RCC) phase I-II trials with 131 I-labeled monoclonal antibody A6H: imaging and pharmacokinetic studies. Proc AACR 1987; 28: 385.

    Google Scholar 

  365. Vigel M, Oster MW, Austin JHM. Spontaneous regression of a pulmonary metastasis after nephrectomy for renal cell carcinoma. J Surg Oncol 1979; 12: 175.

    Article  Google Scholar 

  366. Vosika GJ. Clinical immunotherapy trials of bacterial components derived from mycobacteria and nocardia. J Biol Response Modif 1983; 2(4) 321–342.

    CAS  Google Scholar 

  367. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alpha-2a interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769–1775.

    PubMed  CAS  Google Scholar 

  368. Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alpha-2a in the treatment of colorectal carcinoma. Semin Oncol 1990; 17(1) 16–21.

    PubMed  CAS  Google Scholar 

  369. Wadler S, Wersto R, Weinberg V, et al. Interaction of fluorouracil and interferon in human colon cancer cell lines: Cytotoxic and cytokinetic effects. Cancer Res 1990; 50: 5735–5739.

    PubMed  CAS  Google Scholar 

  370. Wadler S, Lembersky B, Atkins M, et al. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1991; 9: 1806–1810.

    PubMed  CAS  Google Scholar 

  371. Waldman TA, Goldman CK, Bongiovanni KF. Therapy of patients with human T-cell lymphotrophic (sic) virus Iinduced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 1988; 72(5) 1805–1816.

    Google Scholar 

  372. Weese JL, Oldham RK, Tormey DC, et al. Immunologic monitoring in carcinoma of the breast. Surg Gynecol Obstet 1977; 145:208–218.

    Google Scholar 

  373. Weh HJ, Platz D, Braumann D, et al. Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: Preliminary data of a phase II study. Semin Oncol 1992; 19 (Suppl3) 180–184.

    PubMed  CAS  Google Scholar 

  374. Weiner LM, Comis RL. Phase I trial of murine monoclonal antibody administration preceded by recombinant gamma interferon therapy in patients with advanced gastrointestinal carcinoma. Proc ASCO 1986; 5: 225.

    Google Scholar 

  375. Weiner LM, Moldofsky PJ, Gatenby RA, et al. Antibody delivery and effector cell activation in a Phase II trial of recombinant gamma interferon and the murine monoclonal antibody 017-1A in advanced colorectal carcinoma. Cancer Res 1988; 48: 2568–2573.

    PubMed  CAS  Google Scholar 

  376. Weiner LM, O’Dwyer J, Kitson J, et al. A phase I evaluation of the ricin A chain anti-breast carcinoma immunoconjugate 260F9-MAb-rRa. Society for Biological Therapy Meeting Abstracts, 1988. J Biol Response Modif 1989; 8(3) 311.

    Google Scholar 

  377. Weiner LM, Steplewski Z, Koprowski H, et al. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma. Hybridoma 1986; 5(suppl 1) 565–577.

    Google Scholar 

  378. Weisenburger TH, Jones PC, Oahn SS, et al. Active specific intralymphatic immunotherapy in metastatic malignant melanoma: evidence of clinical response. J Biol Resp Modif 1982; 1(1) 57–66.

    Google Scholar 

  379. Welander C, Homesley H, Levin E, Reich S. Phase II trial of the efficacy of human recombinant interferon gamma (rIFN gamma) in recurrent ovarian adenocarcinomas. Proc ASCO 1986; 5: 221.

    Google Scholar 

  380. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor antibodies. Med Phys 1984; 11: 638–645.

    Article  PubMed  CAS  Google Scholar 

  381. West WH. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316(15) 898–905.

    Article  PubMed  CAS  Google Scholar 

  382. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993; 20: 283–295.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biological Therapy Institute Foundation, Franklin, Tennessee, USA

    Robert K. Oldham

  2. University of Missouri, Columbia, Missouri, USA

    Robert K. Oldham

  3. University of Alabama at Birmingham, Birmingham, Alabama, USA

    Scott Ebbinghaus

  4. University of Texas, Galveston, Texas, USA

    M. Ernest Marshall

Authors
  1. Robert K. Oldham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott Ebbinghaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Ernest Marshall
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Biological Therapy Institute Foundation, Franklin, Tennessee, USA

    Robert K. Oldham M.D. (Clinical Professor of Medicine) (Clinical Professor of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Oldham, R.K., Ebbinghaus, S., Marshall, M.E. (1998). Cancer Biotherapy: 1998 Disease-Related Activity. In: Oldham, R.K. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0029-5_22

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0029-5_22

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6501-6

  • Online ISBN: 978-94-009-0029-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation